These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 8169100

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
    Gschwend S, Ebert W, Schultze-Mosgau M, Breuer J.
    Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Nonlinear pharmacokinetic modeling of a gadolinium chelate used as a liver-specific contrast agent for magnetic resonance imaging.
    Schuhmann-Giampieri G.
    Arzneimittelforschung; 1993 Sep; 43(9):1020-4. PubMed ID: 8240452
    [Abstract] [Full Text] [Related]

  • 11. Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system.
    Schuhmann-Giampieri G, Schmitt-Willich H, Press WR, Negishi C, Weinmann HJ, Speck U.
    Radiology; 1992 Apr; 183(1):59-64. PubMed ID: 1549695
    [Abstract] [Full Text] [Related]

  • 12. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging.
    Hamm B, Staks T, Mühler A, Bollow M, Taupitz M, Frenzel T, Wolf KJ, Weinmann HJ, Lange L.
    Radiology; 1995 Jun; 195(3):785-92. PubMed ID: 7754011
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Tissue gadolinium deposition in hepatorenally impaired rats exposed to Gd-EOB-DTPA: evaluation with inductively coupled plasma mass spectrometry (ICP-MS).
    Sato T, Tamada T, Watanabe S, Nishimura H, Kanki A, Noda Y, Higaki A, Yamamoto A, Ito K.
    Radiol Med; 2015 Jun; 120(6):557-62. PubMed ID: 25572545
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Influence of gadolinium chelates on phosphorus-31 magnetic resonance spectroscopy of the liver.
    Bauer H, Negishi C, Weinmann HJ.
    Invest Radiol; 1994 Aug; 29(8):752-7. PubMed ID: 7960625
    [Abstract] [Full Text] [Related]

  • 20. Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence.
    Reimer P, Rummeny EJ, Shamsi K, Balzer T, Daldrup HE, Tombach B, Hesse T, Berns T, Peters PE.
    Radiology; 1996 Apr; 199(1):177-83. PubMed ID: 8633143
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.